NCT06309732View on ClinicalTrials.gov

GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

June 30, 2013

Study Completion Date

January 31, 2014

Conditions
Testicular Neoplasms
Interventions
DRUG

Pegfilgrastim

6mg at each cycle

DRUG

Dactinomycin

1mg/m2

DRUG

Methotrexate

Doses are titrated against renal function. Dosage: 30 mins loading plus 12 hour infusion

DRUG

Etoposide

90mg/m2 injection for infusion

DRUG

Cisplatin

50mg/m2

DRUG

Epirubicin

37.5mg/m2

Trial Locations (1)

EC1A 7BE

Barts and the London NHS Trust, London

All Listed Sponsors
lead

Queen Mary University of London

OTHER

NCT06309732 - GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT) | Biotech Hunter | Biotech Hunter